Welcome and good morning on our behalf as well.
As usual, let's start with the overall highlights of the report.
In terms of the demand situation, the order intake improved compared to last year. Four out of five business areas and more than half of the companies grew organically.
Demand from customers within medical technology and pharmaceuticals was strong, and we also saw improvements in several of the larger customer segments.
Net sales decreased by 2% in total, with a 1% organic decline.
The EBITA margin came in strong at 14.6%. Our companies were also successful in terms of working capital efficiency, and the inventory reductions continued during the quarter. We had a very successful quarter in terms of acquisitions, welcoming six companies during the quarter. Looking more specifically at the order intake and sales trends.
Demand was stronger than last year, with improvements in many companies, customer segments, and geographies. Despite the high order intake, the book-to-bill ratio was slightly negative, partly due to seasonal variations. There were still continued variations between companies and segments, with the strongest growth within medical technology and pharmaceuticals. The demand within the energy sector was at a high level but aggregated slightly lower than last year. Notably, order intake for companies with customers in infrastructure, construction, and engineering improved compared to last year. In terms of sales, they declined by 2% during the quarter due to currency headwinds, divestments, and a 1% organic decline. While acquisitions contributed positively.
There was no impact from the number of working days during the quarter. The organic sales development is primarily explained by the strong references within the business area of life science. The strong reference is linked to sales to Novo Nordisk, which had an organic sales impact of 2% on the group in the quarter.
Excluding sales to Novo Nordisk, the organic growth would have been 1% on group level aggregated. More than half of the companies grew organically during the quarter. Moving into sales per geographical market.
Sales to Sweden were up compared to last year, with improvements in most of the larger customer segments. Sales in Denmark were down, mainly due to strong sales to Novo Nordisk. During the same period last year, Finland and Norway were aggregated as flat year over year compared to the rest of Europe. Sales growth was strong in the Benelux.
Within the process, industry, and energy sectors. UK and Ireland also improved with slightly better demand within general engineering and good development within flow technology.
Products. Sales development was flat in Germany, Switzerland, and Austria. In North America and Asia, sales are slightly volatile, and the development can fluctuate with single projects. In North America, we had a challenging reference due to larger deliveries of valves for power generation in the same period last year, and some of the companies in BA Technology and System Solutions continue to have weaker development due to hesitation from US customers amidst the tariff situation. Sales in Asia improved compared to last year due to strong sales of valves for power generation and also within the marine segment. The total EBITDA decreased by 3% to 1.1 billion, corresponding to an EBITDA margin of 14.6%, slightly lower than 14.8% last year, but still a high level and a clear step up sequentially from 13.7% in Q2. We had a record high Q3 gross margin of 35.5%.
Margin accretive acquisitions and divestments supported as well, but the EBITA margin was dampened by lower organic sales and somewhat higher organic expenses. In terms of the organic expenses, there was around a percentage point year-over-year increase in absolute numbers. I would say that the expense situation overall is under control. There is still a cluster of companies which can improve somewhat. However, the majority of the companies are growing, and it's likely we'll see some expense increases linked to this. Looking at net sales per business area, as mentioned, the same number of working days in the quarter, but a slightly lower order book coming into the quarter and strong references resulted in a slightly negative organic sales development for the group as a whole.
Organic sales were up 3% in the business area of process, energy, and water.
For instance, many other Swedish companies experienced good development, and the Finnish process industry also saw improvements in technology and system solutions.
Sales were unchanged. Infrastructure and construction and industrial and engineering continued to be impacted by the weak general business climate.
Business area Life Science had a 5% organic sales drop due to the strong sales to Novo Nordisk in the same period last year.
Excluding this, life science would have had a positive organic sales growth of 6%.
The business area continued to show good development, with growth in the single-use sector and also in medical technology distribution during the quarter. The EBITA margin improved in two of the five business areas, with the most significant improvement in infrastructure and construction, mainly due to acquisitions and divestments.
Life Science managed to improve the margin despite the lower organic sales.
They had strong gross margin development due to a favorable product mix, some currency tailwind, and good work on pricing in many companies.
In the other three business areas, the EBITDA margin was basically in line with last year.
Since the beginning of the year, we have added ten new companies to the group, with total annual sales of approximately 1.1 billion SEK. After a somewhat slower start to the year, acquisitions accelerated in the third quarter. The acquisition pace improved in the third quarter with six acquisitions completed in the fourth quarter. We have so far welcomed one company.
We are working with several projects in different stages, so we look forward to welcoming a few more companies in the remainder of the year. Our new organization with business segment leaders is also generating more internal leads than before. Looking at the longer trend, more importantly, we are incrementally increasing the number of acquisitions per year, as can be seen in the yellow line to the left.
Although the number of acquisitions per year can be a bit volatile. Looking at the bridge effects from acquisitions, over the last 12 months, we have added 140 million SEK to the group's EBITDA in 2025.
Five. Furthermore, we can also see that the acquisitions are margin accretive, with an accumulated EBITDA margin of 16.4% for the quarter and over 17% rolling 12 months. By that, I hand over to Patrik to comment more on the financials.